The final major SGLT2 inhibitor clinical trial is the Evaluation of Ertugliflozin efficacy and Safety Cardiovascular Outcomes (VERTIS) study [53], where the effect of Ertugliflozin in patients with both T2D and Cardiovascular Disease was investigated. Here, SLC5A2 is linked to type 2 diabetes mellitus.